US HIV/AIDS Funding Crisis Global Shortfall Threatens Lives

The U.S. government’s decision to pause foreign assistance in January 2025 has sparked a global funding crisis for HIV/AIDS programs. A UNAIDS report warns that this shortfall could result in an additional six million infections and four million deaths by 2029.

At its November 2025 replenishment summit, the Global Fund to Fight AIDS, Tuberculosis and Malaria raised $11.34 billion, well below the $18 billion target for 2027–2029. The United States, the Fund’s largest contributor, cut its pledge from the previously announced $6 billion to $4.6 billion, though it remains the primary donor. This partial funding threatens to strain existing programs and delay critical interventions.

HIV remains a major global health challenge, having claimed an estimated 44.1 million lives to date. In 2024, about 40.8 million people were living with HIV, with 65 % of them in sub‑Saharan Africa. More than 11 million individuals had unsuppressed viral loads last year, highlighting gaps in treatment coverage.

Global Fund Executive Director Anne Phelan warned that the “old model” of heavy reliance on international donors is unsustainable and urged nations to prioritize domestic financing. However, she cautioned that abrupt transitions could destabilize health systems. Public‑health expert Melanie Bisnauth advocates a multi‑pronged approach: integrating HIV services into primary care, leveraging domestic resources through taxation and insurance schemes, negotiating lower drug prices, and strengthening regional procurement networks to reduce costs.

The reduction in U.S. funding has already caused immediate disruptions, including shortages of antiretroviral therapies and HIV‑prevention supplies, as well as potential job losses in the health sector that could create service inefficiencies. Programs in affected regions have scaled back services, while governments face pressure to reallocate limited domestic resources or seek alternative donors.

Prolonged funding uncertainty threatens to reverse decades of progress, eroding public trust in health systems and increasing the risk of drug resistance and poorer health outcomes. These developments underscore the urgent need for African nations to diversify funding through domestic resources and innovative partnerships, while global donors must sustain their commitments to prevent catastrophic setbacks in HIV/AIDS control.